Status:
COMPLETED
Evaluation of Malondialdehyde in Periodontal and Cardiovascular Disease
Lead Sponsor:
University of Messina
Conditions:
Metabolic Disease
Eligibility:
All Genders
20-70 years
Brief Summary
Malondialdehyde (MDA) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and coronary heart disease (CHD). The investigators compared the impact of g...
Detailed Description
The aim of this study was to evaluate a possible association between both saliva and serum MDA levels in patients with CP and with CHD and if the serum MDA levels are mediated by serum CRP
Eligibility Criteria
Inclusion
- Presence of at least twenty teeth
- CP with a minimum of 40% of sites with a clinical attachment level (CAL)
- ≥2mm and probing depth (PD) ≥4mm;
- Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
- Presence of ≥40% sites with bleeding on probing (BOP)
Exclusion
- Intake of contraceptives
- Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
- Status of pregnancy or lactation
- Previous history of excessive drinking
- Allergy to local anaesthetic
- Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.
Key Trial Info
Start Date :
January 3 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2019
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT04030286
Start Date
January 3 2014
End Date
April 1 2019
Last Update
July 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Messina
Messina, Italy, 98125